Abacavir/lamivudine combination in the treatment of HIV: a review

References

• DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC) Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. URL: http://AIDSinfo.nih.govAccessed Nov 3, 2008.
   Google Scholar
• McDowellJAChittickGEStevensCPPharmacokinetics of [(14C)] abacavir, a human immunodeficiency virus type-1 (HIV) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance studyAntimicrob Agents Chemother1999432855286110582871
   PubMed Web of Science ®Google Scholar
• McDowellJALouYSymondsWSSteinDSMultiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adultsAntimicrob Agents Chemother2000442061206710898676
   PubMed Web of Science ®Google Scholar
• van PraagRMvan HeeswijkRPJurriaansSPenetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus Type 1Clin Infect Dis200133e91e9211565093
   PubMed Web of Science ®Google Scholar
• LamarcaAClumeckNPlettenbergAEfficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL 30001 Study)J Acquir Immune Defic Syndr20064159860616652033
   PubMed Web of Science ®Google Scholar
• PilerioPShachoy-ClarkADParaMA study examining the pharmacokinetics of abacavir and the intracellular carbovir triphosphate (GSK Protocol CAN10905). [abstract] Intersci ConfAntimicrob Agents Chemother200343914–17: abstract A-1797.
   Google Scholar
• KewnSHoggardPGSalesSDDevelopment of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immuno-deficiency virus-infected patientsAntimicrob Agents Chemother2002461354311751124
   PubMed Web of Science ®Google Scholar
• HarrisMBackDKewnSJuthaSMarinaRMontanerJSIntracellular carbovir triphosphate levels in patients taking abacavir once a dayAIDS20021611969712004286
   PubMed Web of Science ®Google Scholar
• DrusanoGLBilelloPASymondsWTPharmacodynamics of abacavir in an in vitro hollow-fiber model systemAntimicrob Agents Chemother20024646447011796359
   PubMed Web of Science ®Google Scholar
• MoyleGBoffitoMFletcherCSteady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjectsJ Antimicrob Chemother200915321538
   Google Scholar
• KeiserPNassarNSkiestDComparison of symptoms of influenza A with abacavir-associated hypersensitivity reactionInt J STD & AIDS20031447848112869229
   PubMed Web of Science ®Google Scholar
• CutrellAGHernandezJEFlemingJWUpdated clinical risk factor analysis of suspected hypersensitivity reactions to abacavirAnn Pharmacother2004382171217215536137
   PubMed Web of Science ®Google Scholar
• ThurmondLMThorbornDRavitchJImmunohistologic characterization of skin rash observed in patients on abacavir who experience a hypersensitivity reactionAntivir Ther20005Suppl 553 (abstract P51).
   Google Scholar
• SymondsWCutrellAEdwardsMRisk factor analysis of hypersensitivity reactions to abacavirClin Ther20022456557312017401
   PubMed Web of Science ®Google Scholar
• WalenskyRPGoldbergJHDailyJPAnaphylaxis after rechallenge with abacavirAIDS199913999100010371187
   PubMed Web of Science ®Google Scholar
• EasterbrookPJWatersAMuradSEpidemiological risk factors for hypersensitivity reactions to abacavirHIV Med2003432132414525543
   PubMedGoogle Scholar
• LoeligerAESteelHMcGuirkSPowellWSHetheringtonSVThe abacavir hypersensitivity reaction and interruptions in therapyAIDS2001151325132611426085
   PubMed Web of Science ®Google Scholar
• EPZICOM™ (abacavir sulfate and lamivudine) tablets [product information]Research triangle Park, North CarolinaGlaxoSmithKline32006
   Google Scholar
• HetheringtonSMcGuirkSPowellGHypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavirClin Ther2001231603161411726000
   PubMed Web of Science ®Google Scholar
• DargereSVerdonRBouhierKBazinCDisseminated intravascular coagulation as a manifestation of abacavir hypersensitivity reactionAIDS2002161696169712172098
   PubMed Web of Science ®Google Scholar
• BourezaneYSalardDHoenBVandelSDrobacheffCLaurentRDRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapyClin Infect Dis199827132113229827291
   PubMed Web of Science ®Google Scholar
• BossiPColinDBricaireFCaumesEHypersensitivity syndrome associated with efavirenz therapyClin Infect Dis20003022722810619772
   PubMed Web of Science ®Google Scholar
• RyanCMadalonMWorthamDWGrazianoFMSulfa hypersensitivity in patients with HIV infection: onset, treatment, critical review of the literatureWMJ19989723279617304
   PubMedGoogle Scholar
• WolfCRSmithGSmithRLScience, medicine, and the future: PharmacogeneticsBMJ200032098799010753155
   PubMed Web of Science ®Google Scholar
• KoopmansPPvan der VenALVreeTBvan der MeerJWPathogenesis of hypersensitivity reactions to drugs in patients with HIV infection: allergic or toxic?AIDS199592172227755908
   PubMed Web of Science ®Google Scholar
• PeyrieereHNicolasJSiffertMDemolyPHillaire-BuysDReynesJHypersensitivity related to abacavir in two members of a familyAnn Pharmacother2001351291129211675863
   PubMed Web of Science ®Google Scholar
• HetheringtonSHughesARMostellerMGenetic variations in HLA-B region and hypersensitivity reactions to abacavirLancet20023591121112211943262
   PubMed Web of Science ®Google Scholar
• MallalSNolanDWittCAssociation between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavirLancet200235972773211888582
   PubMed Web of Science ®Google Scholar
• MartinAMNolanDGaudieriSPredisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variantProc Natl Acad Sci U S A20041014180418515024131
   PubMed Web of Science ®Google Scholar
• RauchANolanDMartinAMcKinnonEAlmeidaCMallalSProspective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort studyClin Infect Dis2006439910216758424
   PubMed Web of Science ®Google Scholar
• ReevesIChurchillDFisherMScreening for HLA-B*5701 reduces the frequency of abacavir hypersensitivity reactionsAntivir Ther200611Suppl 3L11 (abstract 14).
   Google Scholar
• MallalSPhillipsECarosiGHLA-B*5701 Screening for hypersensitivity to abacavirN Engl J Med200835856857918256392
   PubMed Web of Science ®Google Scholar
• SaagMBaluRPhillipsEHigh sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patientsClin Infect Dis2008461111111818444831
   PubMed Web of Science ®Google Scholar
• WitFWWoodRHorbanAPrednisone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapineAIDS2001152423242911740193
   PubMed Web of Science ®Google Scholar
• DAD Study Group* Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the DAD study: a multi-cohort collaborationLancet20083711417142618387667
   PubMed Web of Science ®Google Scholar
• Strategies for Management of Anti-Retroviral Therapy/INSIGHTDAD Study GroupsUse of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patientsAIDS200822F17F2418753925
   PubMed Web of Science ®Google Scholar
• BrothersCHHernandezJECutrellAGRisk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjectsJ Acquir Immune Defic Syndr200951202819282778
   PubMed Web of Science ®Google Scholar
• BedimoRWestfallADrechslerHTebasPAbacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAART era5th IAS Conference on HIV Pathogenesis, Treatment and PreventionJuly 19–22, 2009Cape Town Abstract MOAB202.
   Google Scholar
• BensonCARibaudoHZhengENo Association of Abacavir (ABC) Use with Risk of Myocardial Infarction (MI) or Severe Cardiovascular Disease Events (SCVD): Results from ACTG A5001/ALLRT16th CROI Conference on Retroviruses and Opportunistic Infections MontrealCanadaFebruary 8–11, 2009
   Google Scholar
• BrunoRRegazziMBCiappinaVComparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIVClin Pharmacokinet20014069570011605717
   PubMed Web of Science ®Google Scholar
• MooreKHBarrettJEShawSThe pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1AIDS1999132239225010563709
   PubMed Web of Science ®Google Scholar
• YuenGJLouYBumgamerNFEquivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice dailyAntimicrob Agents Chemother20044817618214693537
   PubMed Web of Science ®Google Scholar
• MooreKHYuenGJRaaschRHPharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazoleClin Pharmacol Ther1996595505588646826
   PubMed Web of Science ®Google Scholar
• McDowellJAChittickGEStevensCPEdwardsKDSteinDSPharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adultsAntimicrob Agents Chemother2000441686169010817729
   PubMed Web of Science ®Google Scholar
• DejesusEHerreraGTeofiloEAbacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naïve HIV-infected adultsCin Infect Dis20043910381046
   PubMed Web of Science ®Google Scholar
• MacArthurRDChenLPengGEfficacy and Safety of Abacavir Plus Lamivudine Versus Didanosine Plus Stavudine When Combined with a Protease Inhibitor, a Nonnucleoside Reverse Transcriptase Inhibitor, or Both in HIV-1 Positive Antiretroviral-Naive PersonsHIV Clin Trials2004536137015682349
   PubMed Web of Science ®Google Scholar
• SaxPTierneyCCollierAACTG 5202: Shorter time to virologic failure with ABC/3TC than tenofovir/FTC in treatment-naive subjects with HIV RNA > 100, 00017th International AIDS ConferenceAug 3–8, 2008Mexico City, Mexico Abstract THAB0303.
   Google Scholar
• SmithKYPatelPFineDRandomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatmentAIDS2009231547155619542866
   PubMed Web of Science ®Google Scholar
• Rodriguez-FrenchABoghossianJGrayGEThe NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naïve HIV-1-infected patientsJ Acquir Immune Defic Syndr200435223214707788
   PubMed Web of Science ®Google Scholar
• GatheJCJrIvePWoodRSOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naïve HIV-1-infected patientsAIDS2004181529153715238771
   PubMed Web of Science ®Google Scholar
• MoyleGJDejesusECahnPAbacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naïve HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination StudyJ Acquir Immune Defic Syndr20053841742515764958
   PubMed Web of Science ®Google Scholar
• BartlettJAJohnsonJHerreraGLong term-results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or StavudineJ Acquir Immune Defic Syndr20064328429216967040
   PubMed Web of Science ®Google Scholar
• EronJJrYeniPGatheJJrThe KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trialLancet200636847648216890834
   PubMed Web of Science ®Google Scholar
• SosaNHill-ZabalaCDejesusEAbacavir and lamivudine fixed-dose combination tablet once-daily compared with abacavir and lamivudine twice-daily in HIV-1 infected patients over 48 weeks (ESS30008, SEAL)J Acquir Immune Defic Syndr20054042242716280696
   PubMed Web of Science ®Google Scholar
• GulickRRibaudoHShikumaCTriple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infectionN Engl J Med20043501850186115115831
   PubMed Web of Science ®Google Scholar
• JohnsonAARayASHanesJToxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymeraseJ Biol Chem2001276408474085711526116
   PubMed Web of Science ®Google Scholar
• KakudaTNPharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicityClin Ther20002268570810929917
   PubMed Web of Science ®Google Scholar
• BirkusGHitchcockMJCihlarTAssessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitorsAntimicrob Agents Chemother20024671672311850253
   PubMed Web of Science ®Google Scholar
• MoyleGJDattaDMandaliaSMorleseJAsboeDGazzardBGHyperlactaemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factorsAIDS2002161341134912131210
   PubMed Web of Science ®Google Scholar
• PodzamczerDFerrerESanchezPLess lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized studyJ Acquir Immune Defic Syndr20074413914717106274
   PubMed Web of Science ®Google Scholar
• CarrAWorkmanCSmithDEAbacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: randomized trialJAMA200228820721512095385
   PubMed Web of Science ®Google Scholar
• ShlayJVisnegarwalaFBartschGBody composition and metabolic changes in antiretroviral-naïve patients randomized to didanosine and stavudine vs abacavir and lamivudineJ Acquir Immune Defic Syndr20053814715515671799
   PubMed Web of Science ®Google Scholar
• McComseyGWardDHessenthalerSLipoatrophy improvement following switch to ABC or AZT from D4T, Tarheel studyClin Infec Dis20043826327014699460
   PubMed Web of Science ®Google Scholar
• D’AquilaRTSchapiroJMBrun-VezinetFDrug resistance mutations in HIV-1Top HIV Med200210212512717052
   PubMedGoogle Scholar
• EronJJBenoitSLJemsekJTreatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working PartyN Engl J Med1995333166216697477218
   PubMed Web of Science ®Google Scholar
• FrankelFAInvernizziCFOliveiraMWainbergMADiminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutationsAIDS20072166567517413687
   PubMed Web of Science ®Google Scholar
• TisdaleMAlnadafTCousensDCombination of mutations in human immunodeficiency virus Type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89Antimicrob Agents Chemother199741109410989145875
   PubMed Web of Science ®Google Scholar
• Brun-VezinetFDeschampsRuffaultAClinically relevant interpretation of genotype for resistance to abacavirAIDS2003171795180212891065
   PubMed Web of Science ®Google Scholar
• WalterHSchmidtBWerveinMPrediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivoAntimicrob Agents Chemother200246899411751116
   PubMed Web of Science ®Google Scholar
• Van LaethemKWitvrouwMBalzariniJPatient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavirAIDS20001446947110770556
   PubMed Web of Science ®Google Scholar